LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca’s drug Truqap, in combination with Faslodex, for treating certain advanced breast cancer cases. The positive opinion is based on the CAPItello-291 Phase III trial results, which showed a 50% reduction in disease progression or death compared…